Poster zum Thema "CGRP inhibitors in the clinic"

Zurück
  • P104
A Phase 2/3 Open-label, Long-term, Safety Trial of Zavegepant 10 mg Nasal Spray for the Acute Treatment of Migraine
  • Robert Croop (Nerw Haven, CT/ US)
  • P115
Rimegepant for the Acute Treatment of Migraine: Subgroup Analyses From 3 Phase 3 Clinical Trials by Triptan Treatment Experience
  • P122
Oral Rimegepant 75 mg is Safe and Well Tolerated in Adults With Migraine and Cardiovascular Risk Factors: Results of a Multicenter, Long-Term, Open-Label Safety Study
  • P123
Medication Preference, Satisfaction, and Clinical Improvement Among Adults Receiving Long-Term Treatment With Rimegepant for Migraine
  • P125
Concomitant treatment of anti-CGRP and botulinum toxin in resistant migraine, is it useful for our patients?
  • P136a
Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial
  • P14
Efficacy and safety of Galcanezumab as chronic cluster headache preventive treatment in real world conditions
  • P145
Impact of migraine attack accompanying symptoms in treatment response to anti-CGRP monoclonal antibodies treatment and their evolution after 6 months
  • P148
Effects of Rimegepant 75 mg on Monthly Migraine Days: a 52-Week, Open-Label Extension Study
  • P149
Safety and Tolerability of Rimegepant Every Other Day for Preventive Treatment of Migraine Plus As-Needed for Acute Treatment of Migraine: Results from A 52-Week, Open-Label Extension Study
  • P151
Long-term Effectiveness and Safety of Erenumab in patients with Migraine: a Systematic Review and Single-Arm Meta-analysis
  • P154
Evaluation of a mandatory drug holiday during treatment with monoclonal antibodies targeting the cgrp pathway: a patient survey
  • P16
Galcanezumab for refractory chronic cluster headache in clinical practice
  • P162
Efficacy and safety of once monthly subcutaneous erenumab 70 mg in adult chronic migraine patients (primary analysis): Indian sub analysis from Global DRAGON study
  • P174
HEADWORK as innovative tool for monitoring MABs efficacy in migraine and their influence on work activity.
  • P175
Optimization of Acute Treatment in Migraine Patients Treated with Monoclonal Antibodies Acting on the CGRP Pathway
  • P257
Switching from anti-CGRP-receptor mAb (erenumab) to an anti-CGRP-molecule mAbs (fremanezumab) in chronic migraine: results of a real-world study
  • P258
REAL-WORLD FREMANEZUMAB EXPERIENCE FROM HEADACHE CLINIC IN MOSCOW
  • P259
Discontinuation after one-year of treatment with anti-CGRP antibodies did not provide long-term sustained response without therapy
  • P260
Anti-CGRP monoclonal antibodies and peripheral sensitization: a study on Pressure Pain Threshold in migraineurs
  • P261
Clinical characteristics, efficacy and safety of patients older than 65 years with the use of anti-CGRP drugs in the central region of Spain
  • P262
Is it worth switching monoclonal antibodies?
  • P263
Study on the presence of comorbidities in a series of 200 patients with migraine and their influence on the effectiveness of fremanezumab.
  • P264
Predictors of galcanezumab response in Korean patients with migraine
  • P265
Can We Descriminate Migraine Susceptibile to CGRP Antagonism?
  • P266
Interim Analysis on the Effectiveness of Fremanezumab for the Preventive Treatment of Migraine: The Observational PEARL Study
  • P267
Response patterns in migraine patients in prophylactic treatment with different anti-CGRP pharmacological blockade systems
  • P268
Effect of Galcanezumab in Migraine and Concomitant Medication Overuse Headache Without Prior Drug Withdrawal
  • P269
Factors associated with favorable outcome in galcanezumab treatment for chronic migraine: A clinic-based prospective study
  • P270
Past Preventive Migraine Treatment in Patients Initiating Fremanezumab in Clinical Practice: Interim Data from the PEARL Study
  • P271
Fremanezumab in patients with refractory migraine and medication-overuse headache: the experience of a tertiary Portuguese hospital
  • P272
Descriptive study on the presence, treatment and evolution of comorbidities in a series of 200 migraine patients treated with fremanezumab.
  • P273
Response to fremanezumab in migraine patients with and without prior aCGRP mAbs - preliminary data from the FINESSE study
  • P274
Could Symptom Severity Predict the Response to Anti-Cgrp Monoclonal Antibodies in Migraine?
  • P49
Use of anti-CGRP monoclonal antibodies in pediatric migraine: first evaluations of a phase 3, randomized, double-blind, placebo-controlled study
  • P50
Real-world Reductions in Monthly Migraine Days and Migraine-Related Healthcare Resource Utilization in UK Patients Using Fremanezumab
  • P51
Anti-CGRP mAbs in a difficult to treat migraine population. Efficacy and safety.
  • P52
The efficacy of CGRP monoclonal antibodies – an Australian experience
  • P53
Use of non-pharmacological therapies in individuals with migraine eligible for treatment with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP)-signaling: a single-center cross-sectional observational study
  • P54
Role of Monoclonal Antibodies Against the Calcitonin Gene-Related Peptide or Receptor (CGRP-Mabs) for Chronic Migraine Prevention: A Critical Review
  • P55
Real Life Experience: Use of CGRP Inhibitors in Patients Older than 55 Years Old, are they Safe and Effective?
  • P56
Real life experience and learning curve of Galcanezumab in migraine. Galca-only Consortium
  • P57
Real-world Experience with Galcanezumab for the Preventive Treatment of Cluster Headache
  • P58
Recurrent painful ophthalmoplegic neuropathy treated with erenumab: A case report
  • P59
Investigating the Long-Term Efficacy of Calcitonin Gene Related Peptide Monoclonal Antibodies
  • P60
Brain connectivity modifications induced by monoclonal antibodies targeting the CGRP pathway in migraine patients: a prospective HD-EEG, open-label, study
  • P79
Impact of SARS-CoV2 vaccine on migraine course in patients receiving CGRP monoclonal antibodies